Report Content
Chapter 1 Methodology & Scope
1.1 Market definitions
1.2 Base estimates & working
1.2.1 Data collection
1.3 Forecast calculations
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Premature rupture of membranes (PROM) testing industry 3600 synopsis, 2018 - 2032
2.2 Business trends
2.3 Regional trends
2.4 Product type trends
2.5 End-use trends
Chapter 3 Premature Rupture of Membranes (PROM) Testing Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic diseases worldwide
3.2.1.2 Rising technological advancements in nuclear imaging systems
3.2.1.3 Rise in healthcare expenditure
3.2.1.4 Favourable government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of the nuclear imaging devices
3.2.2.2 Lack of skilled or trained personnel in the developing and underdeveloped region
3.3 Growth potential analysis
3.3.1 By product type
3.3.2 By end-use
3.4 COVID-19 impact analysis
3.5 Technology landscape
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Porter's analysis
3.8 PESTEL analysis
Chapter 4 Competitive landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive dashboard, 2022
4.4 Company market share analysis, 2022
4.5 Competitive analysis of major market players
4.6 Competitive positioning matrix
4.7 Strategic outlook matrix
Chapter 5 Premature Rupture of Membranes (PROM) Testing Market and Forecast, By Product Type (USD Million)
5.1 Key trends, by product type
5.2 Nitrazine test
5.3 Ferning test
5.4 Pooling test
5.5 Ultrasound
5.6 Others
Chapter 6 Premature Rupture of Membranes (PROM) Testing Market and Forecast, By End-use (USD Million)
6.1 Key trends, by end-use
6.2 Hospitals
6.3 Diagnostic laboratories
6.4 Others
Chapter 7 Premature Rupture of Membranes (PROM) Testing Market and Forecast, By Region (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Spain
7.3.5 Italy
7.3.6 Switzerland
7.3.7 Netherlands
7.3.8 Poland
7.3.9 Sweden
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 New Zealand
7.4.7 Indonesia
7.4.8 Thailand
7.4.9 Vietnam
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Colombia
7.5.5 Chile
7.5.6 Peru
7.6 Middle East & Africa
7.6.1 South Africa
7.6.2 Saudi Arabia
7.6.3 UAE
7.6.4 Iran
Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.2 QIAGEN
8.3 Hologic, Inc.
8.4 Medix Biochemica
8.5 Biosynex
8.6 Clinical Innovations LLC
8.7 Sera Prognostics Inc.
8.8 The Cooper Companies Inc.
8.9 NX Prenatal Inc.
8.10 IQ Products
